Back to discover
Disease

Fallopian Tube Neoplasms

Late-stage therapeutic developmentEmerging research
MeSHFallopian Tube Neoplasms
2
Publications
18
Clinical trials
2
Related conditions
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.

Research2024-12-03Gynecologic oncology

Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

Research2013-10-22International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 3 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones5View
Results posted 1
Results expected 3
Recently completed 1
Activity timeline5

Clinical trials

15 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
9
Late-stage
6
Completed
Late-stage studies

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).

Phase 3 · Recruiting · Swiss GO Trial Group

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Phase 3 · Active, not recruiting · CanariaBio Inc.

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Phase 3 · Recruiting · Eli Lilly and Company

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer (KEYNOTE-B96/ENGOT-ov65)

Phase 3 · Active, not recruiting · Merck Sharp & Dohme LLC

A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 3 · Completed · AGO Study Group

Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma

Phase 3 · Completed · Eli Lilly and Company
Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).

Phase 3 · Recruiting · Swiss GO Trial Group

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Phase 3 · Recruiting · Eli Lilly and Company

Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors

Phase 2 · Recruiting · Instituto do Cancer do Estado de São Paulo

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

Phase 1 · Recruiting · Bio-Path Holdings, Inc.
Recently completed

An Indian Multicentric, Open Label, Prospective Phase 4 Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice

Phase 4 · Completed · Hoffmann-La Roche

An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Phase 2 · Completed · Imperial College London

A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

Phase 3 · Completed · AGO Study Group

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 · Completed · Janssen Research & Development, LLC

Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma

Phase 3 · Completed · Eli Lilly and Company

A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy

Phase 3 · Completed · Eli Lilly and Company

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142025
Most influential

Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2014 · 883 cites

Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.

Gynecologic oncology · 2025 · 10 cites
Recent publications

Analysis of real world FRα testing in ovarian, fallopian tube, and primary peritoneal cancers.

Gynecologic oncology · 2025 · 10 cites

Staging classification for cancer of the ovary, fallopian tube, and peritoneum.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2014 · 883 cites
Major themes5
  • Carcinoma, Ovarian Epithelial1
  • Fallopian Tube Neoplasms1
  • Folate Receptor 11
  • Ovarian Neoplasms1
  • Peritoneal Neoplasms1
Leading journals2
  • Gynecologic oncology1
  • International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics1
Leading researchers8
  • Armetta J1
  • Biorn M1
  • Caveney B1
  • Cooper M1
  • Green M1
  • Klein JL1
  • Ko H1
  • Lyon E1
Affiliations (unnormalised)3
  • University of Virginia1
  • USA; Duke University Medical Center1
  • USA; Wake Forest Comprehensive Cancer Center and Department of Pathology1

Related conditions

2 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Ovarian Neoplasms2Peritoneal Neoplasms2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.

Identifiers
MeSHFallopian Tube Neoplasms
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.